Specifications
- Purity
- ≥99% (HPLC)
- Appearance
- White or slightly yellow, fine powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO (10 mg/ml), water (insoluble)
- Melting Point
- 66.0-69.0 °C
Available from stock
Caroverin
- SKU
- C0260
Category: API's & Intermediates
- Synonyms
- 1-[2-(Diethylamino)ethyl]-3-(p-methoxybenzyl)-2-quinoxalone
- 23465-76-1
- CAS-Number
- C22H27N3O2
- Molecular Formula
- 365.47
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- RT
- Long Term Storage
- +4°C
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at +4°C.
- Hazard statements
- H302
- Precautionary statements
- P264, P270, P301+P312, P330, P501
- GHS Symbol
- GHS07
- Signal word
- Warning
- Transportation
- Not dangerous goods
- Description
- Quinoxaline compound, originally developed as a spasmolytic drug. Acts as an N-type calcium channel blocker, competitive AMPA receptor antagonist, and non-competitive NMDA receptor antagonist. Antioxidant agent through partial prevention of the formation and the highly active scavenging of hydroxyl radicals. Used to treat inner ear diseases such as tinnitus. Shown to inhibit tumor-promoting factors and potentially useful as a chemotherapeutic agent.
- Smiles
- O=C1N(CCN(CC)CC)C2=C(C=CC=C2)N=C1CC3=CC=C(OC)C=C3
- InChi Key
- MSPRUJDUTKRMLM-UHFFFAOYSA-N
- References
- Y. Ishida, et al., Br. J. Pharmacol. 71, 343 (1980) , B. Saletu, et al., Arzneimittelforsch. 45, 217 (1995) , D.M. Denk, et al., Acta Otolaryngol. 117, 825 (1997) , H. Nohl, et al., Biofactors 19, 79 (2003) , G. Haymerle, et al., Eur. Arch. Otorhinolaryngol. 272, 3451 (2015)
- InChi
- InChI=1S/C22H27N3O2/c1-4-24(5-2)14-15-25-21-9-7-6-8-19(21)23-20(22(25)26)16-17-10-12-18(27-3)13-11-17/h6-13H,4-5,14-16H2,1-3H3
Quinoxaline compound, originally developed as a spasmolytic drug. Acts as an N-type calcium channel blocker, competitive AMPA receptor antagonist, and non-competitive NMDA receptor antagonist. Antioxidant agent through partial prevention of the formation and the highly active scavenging of hydroxyl radicals. Used to treat inner ear diseases such as tinnitus. Shown to inhibit tumor-promoting factors and potentially useful as a chemotherapeutic agent.
Additional information
| Synonyms | 1-[2-(Diethylamino)ethyl]-3-(p-methoxybenzyl)-2-quinoxalone |
|---|---|
| Purity | ≥99% (HPLC) |
| Appearance | White or slightly yellow, fine powder |
| CAS-Number | 23465-76-1 |
| Molecular Formula | C22H27N3O2 |
| Molecular Weight | 365.47 |
| Identity | 1H-NMR |
| Solvents | DMSO (10 mg/ml), water (insoluble) |
| Melting Point | 66.0-69.0 °C |
| Smiles | O=C1N(CCN(CC)CC)C2=C(C=CC=C2)N=C1CC3=CC=C(OC)C=C3 |
| InChi Key | MSPRUJDUTKRMLM-UHFFFAOYSA-N |
| Shipping | AMBIENT |
| Short Term Storage | RT |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Hazard statements | H302 |
| Precautionary statements | P264, P270, P301+P312, P330, P501 |
| GHS Symbol | GHS07 |
| Signal word | Warning |
| Transportation | Not dangerous goods |
| References | Y. Ishida, et al., Br. J. Pharmacol. 71, 343 (1980), B. Saletu, et al., Arzneimittelforsch. 45, 217 (1995), D.M. Denk, et al., Acta Otolaryngol. 117, 825 (1997), H. Nohl, et al., Biofactors 19, 79 (2003), G. Haymerle, et al., Eur. Arch. Otorhinolaryngol. 272, 3451 (2015) |
| InChi | InChI=1S/C22H27N3O2/c1-4-24(5-2)14-15-25-21-9-7-6-8-19(21)23-20(22(25)26)16-17-10-12-18(27-3)13-11-17/h6-13H,4-5,14-16H2,1-3H3 |
| Quantity | 10 mg, 50 mg, Bulk |
